Bristol-Myers Squibb Company (BMY)

Add a New Bulls Reason Company: Bristol-Myers Squibb Company (BMY) Current price: Headline: (100 character max) Analysis: Cancel 97% agree 36 votes   "Good strategic direction for continued, efficient, research and development" Top Contributor: Kryssia Uraguchi | Created when NYSE:BMY was $30.31 | Edit | History Good strategic direction for continued, efficient, research and development (100 character max) Cancel 100% agree 9 votes   MarketGrader.Com Score 66.6 Buy Created when NYSE:BMY was $20.18 | Edit | History Looking at the cash flow score of A- and the profitability score of A, good yield 6%+ and you have to find reasons not to own this stock Best P/E fit objective of 29. Go to MarketGRader.COm for a peer comparison (100 character max) Cancel 68% agree 16 votes   BMY an acquisition target? Top Contributor: Will Shikani | Created when NYSE:BMY was $20.18 | Edit | History Bristol-Myers Squibb has a low stock price, a decent pipeline, and a lot of cash that they are sitting on right now. This makes them a potential target for merger or acquisition another large pharmaceutical company, as free cash serves as a sort of discount in an M&A situation. (100 character max) Cancel 100% agree 1 votes   Good strategic direction for continued, efficient, research and development Top Contributor: Kryssia Uraguchi | Created when NYSE:BMY was $30.31 | Edit | History Good strategic direction for continued, efficient, research and development (100 character max) Cancel 100% agree 1 votes   Strong late-stage pipeline Top Contributor: Kryssia Uraguchi | Created when NYSE:BMY was $30.31 | Edit | History Strong late-stage pipeline will lead to solid performance in mid-range future. (100 character max) Cancel

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.